Larvol Delta

tarextumab (OMP-59R5) - MorphoSys, Mereo Biopharma, GSK

GSK: R&D Event (GSK) - Nov 5, 2015 - Anticipated regulatory submission in SCLC and pancreatic cancer in 2020
Anticipated regulatory • Oncology • Pancreatic Cancer

http://www.gsk.com/media/851136/r-and-d-event-full-presentation.pdf

Nov 5, 2015